PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1672944
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1672944
Global Psoriatic Arthritis Treatment Market is estimated to be valued at USD 12.19 Bn in 2025 and is expected to reach USD 23.47 Bn by 2032, growing at a compound annual growth rate (CAGR) of 9.8% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 12.19 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 9.80% | 2032 Value Projection: | USD 23.47 Bn |
Psoriatic arthritis is a chronic inflammatory arthritis that occurs in conjunction with psoriasis. It is estimated that around 30% of people with psoriasis may develop psoriatic arthritis. The disease causes pain, stiffness and swelling in and around the joints. Over time, psoriatic arthritis can cause permanent damage to the joints. Conventional treatments including disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and TNF inhibitors are used to manage the symptoms. Global psoriatic arthritis treatment market growth is driven by rising development and approval of novel targeted biologic therapies with better safety and efficacy profiles.
Global psoriatic arthritis treatment market growth is driven by growing prevalence of psoriatic arthritis worldwide. According to estimates, the global prevalence of the disease ranges between 0.06% to 1%. Moreover, increasing awareness about the disease and availability of advanced treatments can also drive the market growth. However, high cost of biologic therapies can hamper the market growth, especially in price-sensitive developing regions. Continued efforts by market players to develop cost-effective generic versions of biologics can reduce costs over time. Furthermore, rising healthcare expenditures in emerging nations can offer new opportunities for the market players in the near future.
This report provides in-depth analysis of the global psoriatic arthritis treatment market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2025-2032), considering 2024 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global psoriatic arthritis treatment market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Johnson & Johnson, AbbVie, Novartis, UCB, Eli Lilly, Bristol-Myers Squibb
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global psoriatic arthritis treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global psoriatic arthritis treatment market
Detailed Segmentation-